Allergen immunotherapy on the way to product-based evaluation—a WAO statement

Allergen immunotherapy (AIT) is widely used in clinical practice for patients with moderate to severe allergic rhinitis due to inhalant allergens and may be delivered via subcutaneous (SCIT) and sublingual routes (SLIT). However, the quality of evidence for individual AIT products is very heterogene...

Full description

Saved in:
Bibliographic Details
Published in:The World Allergy Organization journal Vol. 8; no. 1; pp. 29 - 4
Main Authors: Bachert, Claus, Larché, Mark, Bonini, Sergio, Canonica, Giorgio Walter, Kündig, Thomas, Larenas-Linnemann, Desiree, Ledford, Dennis, Neffen, Hugo, Pawankar, Ruby, Passalacqua, Giovanni
Format: Journal Article
Language:English
Published: London Elsevier Inc 2015
Elsevier BV
BioMed Central
BioMed Central Ltd
Elsevier
Subjects:
Allergens
Allergies
Allergology
Analysis
Asthma
Care and treatment
EUROPE
Evidence-based medicine
Health aspects
Immunologic diseases. Allergy
Immunology
Immunology and Allergy
Immunotherapy
Medical colleges
Medicine
Medicine & Public Health
Medicine and Health Sciences
ORGANIZATION
Position and Guidelines
Position Article and Guidelines
RANDOMIZED CONTROLLED-TRIAL
RC581-607
RECOMMENDATIONS
RHINOCONJUNCTIVITIS
STANDARDIZATION
Allergic Rhinitis
Individual Product
Allergen Immunotherapy
Allergen Extract
Inhalant Allergen
ISSN:1939-4551, 1939-4551
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allergen immunotherapy (AIT) is widely used in clinical practice for patients with moderate to severe allergic rhinitis due to inhalant allergens and may be delivered via subcutaneous (SCIT) and sublingual routes (SLIT). However, the quality of evidence for individual AIT products is very heterogeneous, and extensions of overall conclusions (“class effects”) on the efficacy and disease-modifying effects to all AIT products are unjustified. In contrast, each product needs to be evaluated individually, based on available study results, to justify efficacy and specific claims on sustained and disease modifying effects per allergen and targeted patient group (children vs. adults, allergic rhinitis vs. asthma). WAO intends to support the current development to evidence-based AIT, which ultimately will lead to a more efficacious treatment of allergic patients and the appropriate recognition of AIT.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1939-4551
1939-4551
DOI:10.1186/s40413-015-0078-8